Cargando…

Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor–Positive and HER-2–Negative Breast Cancer with Neoadjuvant Chemotherapy

PURPOSE: This study investigated pathological complete response (pCR) according to androgen receptor (AR) in breast cancer patients undergoing neoadjuvant chemotherapy and estimated the relationship between AR expression and clinicopathological factors. MATERIALS AND METHODS: We identified 624 breas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Eun-Gyeong, Lee, Dong-Eun, Kim, Hyun Hee, Han, Jai Hong, Lee, Seeyoun, Kang, Han-Sung, Lee, Eun Sook, Chae, Heejung, Sim, Sung Hoon, Lee, Keun Seok, Kwon, Youngmee, Jung, So-Youn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101776/ https://www.ncbi.nlm.nih.gov/pubmed/36097802 http://dx.doi.org/10.4143/crt.2022.834

Ejemplares similares

Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer
por: Song, Ran, et al.
Publicado: (2023)

Clinical Effectiveness of Hypofractionated Proton Beam Therapy for Liver Metastasis From Breast Cancer
por: Kim, Tae Hyun, et al.
Publicado: (2021)

Progranulin and Breast Cancer Mortality: 13-Year Follow-Up of a Cohort Study
por: Koo, Dong-Hoe, et al.
Publicado: (2023)

Sentinel Lymph Node Biopsy in Breast Cancer Patients With Pathological Complete Response in the Axillary Lymph Node After Neoadjuvant Chemotherapy
por: Kim, Hyunhee, et al.
Publicado: (2021)

Criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study
por: Kim, Yunju, et al.
Publicado: (2021)

Questionnaire study of application about sentinel lymph node biopsy surgery in locally advanced breast cancer patients who received neoadjuvant chemotherapy
por: Lee, Eun-Gyeong, et al.
Publicado: (2023)

Comparison of clinical outcomes between sentinel lymph node biopsy and axillary lymph node dissection in a single-center Z0011-eligible breast cancer cohort
por: Jo, Heein, et al.
Publicado: (2020)

Surgical outcomes of localization using indocyanine green fluorescence in breast conserving surgery: a prospective study
por: Lee, Eun-Gyeong, et al.
Publicado: (2021)

Interaction Effect Between Breast Density and Reproductive Factors on Breast Cancer Risk in Korean Population
por: Lim, Se-Eun, et al.
Publicado: (2019)

Breast Cancer–Related Lymphedema after Neoadjuvant Chemotherapy
por: Kim, Myungsoo, et al.
Publicado: (2015)

Comparing the Characteristics and Outcomes of Male and Female Breast Cancer Patients in Korea: Korea Central Cancer Registry
por: Lee, Eun-Gyeong, et al.
Publicado: (2020)

Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer
por: Ryu, Jin-Sun, et al.
Publicado: (2019)

Risk Factors for Palbociclib-Induced Early Developing Neutropenia in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
por: Lee, Yeonhong, et al.
Publicado: (2023)

Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy?
por: Eom, Keun-Yong, et al.
Publicado: (2014)

Locoregional Recurrence of Breast Conserving Surgery after Preoperative Chemotherapy in Korean Women with Locally Advanced Breast Cancer
por: Lee, Seeyoun, et al.
Publicado: (2011)

Role of aldehyde dehydrogenases, alcohol dehydrogenase 1B genotype, alcohol consumption, and their combination in breast cancer in East-Asian women
por: Park, Boyoung, et al.
Publicado: (2020)

Dietary Inflammatory Index and Risk of Breast Cancer Based on Hormone Receptor Status: A Case-Control Study in Korea
por: Lee, Seohyun, et al.
Publicado: (2019)

Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers
por: Lee, Eun-Gyeong, et al.
Publicado: (2019)

CKAP2 (cytoskeleton-associated protein2) is a new prognostic marker in HER2-negative luminal type breast cancer
por: Sim, Sung Hoon, et al.
Publicado: (2017)

The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients
por: Lee, Moo Hyun, et al.
Publicado: (2016)

Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
por: Kim, Hee Jeong, et al.
Publicado: (2020)

Oncologic efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy
por: Choi, Hee Jun, et al.
Publicado: (2023)

Identification of Risk Factors for Locoregional Recurrence in Breast Cancer Patients with Nodal Stage N0 and N1: Who Could Benefit from Post-Mastectomy Radiotherapy?
por: Jwa, Eunjin, et al.
Publicado: (2015)

Predicting the Response of Neoadjuvant Chemotherapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer With Axillary Lymph Node Metastasis by Multigene Assay
por: Lee, Jun-Hee, et al.
Publicado: (2022)

Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

The invasive lobular carcinoma as a prototype luminal A breast cancer: A retrospective cohort study
por: Jung, So-Youn, et al.
Publicado: (2010)

Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

The Impact of HER2-Low Expression on Oncologic Outcomes in Hormone Receptor-Positive Breast Cancer
por: Park, Woong Ki, et al.
Publicado: (2023)

The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study
por: Lee, Kyoungmin, et al.
Publicado: (2021)

Utility of (18)F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
por: Lee, In Hee, et al.
Publicado: (2020)

Effects of ginseng on two main sex steroid hormone receptors: estrogen and androgen receptors
por: Park, Joonwoo, et al.
Publicado: (2017)

Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers
por: Choi, Byoungsan, et al.
Publicado: (2020)

Ki-67 Expression is a Significant Prognostic Factor Only When Progesterone Receptor Expression is Low in Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer
por: Kang, Young-Joon, et al.
Publicado: (2019)

Identification of Prognostic Risk Factors for Transient and Persistent Lymphedema after Multimodal Treatment for Breast Cancer
por: Kim, Myungsoo, et al.
Publicado: (2016)

Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
por: Kim, Hee Jeong, et al.
Publicado: (2015)

The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in Korea
por: Lee, Moo Hyun, et al.
Publicado: (2015)

Could axillary lymph node dissection be omitted in the mastectomy patient with tumor positive sentinel node?
por: You, Ji Young, et al.
Publicado: (2023)

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
por: You, Ji Young, et al.
Publicado: (2023)

Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia
por: Yun, Sung-Il, et al.
Publicado: (2022)

The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer
por: Joung, Jae Young, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7iabhgk2a3577gp52phnifkvhc